Loading news...
OPKO Health, Inc. (NASDAQ: OPK - Get Free Report) has received a consensus rating of "Hold" from the seven brokerages that are currently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, three have issued a hold rating, two have assigned a buy rating and one has issued a
OPK rides on RAYALDEE strength and partnerships, but revenue decline, losses, and reliance on a single drug cloud its near-term outlook.
OPKO Health (NASDAQ: OPK - Get Free Report) and Hypertension Diagnostics (OTCMKTS:HDII - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation. Earnings and Valuation This table compares OPKO Health
OPKO Health beats Q4 earnings and revenue estimates, but sales decline and gross margin narrows.
MIAMI, Feb. 27, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK) announced today that management will be participating in the Jefferies Biotech on the Beach Summit, being held March 10-11, 2026, at 1 Hotel South Beach in Miami. Management will be holding one-on-one meetings with investors registered for the event on Wednesday, March 11th.
OPKO Health (NASDAQ: OPK - Get Free Report) and Sintx Technologies (NASDAQ: SINT - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, earnings, valuation, profitability, dividends, institutional ownership and analyst recommendations. Analyst Recommendations This is a summary of
OPKO Health, Inc. (OPK) Q4 2025 Earnings Call Transcript
While the top- and bottom-line numbers for OPKO Health (OPK) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
OPKO Health (OPK) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to earnings of $0.01 per share a year ago.
MIAMI, Feb. 26, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three and 12 months ended December 31, 2025, and introduces financial guidance for the first quarter and full year 2026. Highlights from the fourth quarter of 2025 and recent weeks include the following: Entered into a research collaboration with Regeneron Pharmaceuticals to develop multispecific antibodies.
OPKO Health (NASDAQ: OPK - Get Free Report) is projected to post its Q4 2025 results after the market closes on Thursday, February 26th. Analysts expect OPKO Health to post earnings of ($0.07) per share and revenue of $139.7570 million for the quarter. Interested persons can check the company's upcoming Q4 2025 earning summary page for
OPKO Health, Inc. OPK is well-poised for growth in the coming quarters, supported by the potential of RAYALDEE. The optimism surrounding the stock is backed by RAYALDEE's performance and strategic partnerships.
MIAMI, Feb. 12, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three and 12 months ended December 31, 2025, after the close of the U.S. financial markets on Thursday, February 26, 2026. OPKO's senior management will provide a business update and discuss results as well as financial guidance during a conference call and live audio webcast beginning at 4:30 p.m. Eastern time.
Coloplast A/S (OTCMKTS:CLPBY - Get Free Report) and OPKO Health (NASDAQ: OPK - Get Free Report) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations. Institutional and Insider Ownership 64.6% of OPKO Health
This is the third program that s uccessfully combine s Entera's oral peptide N- Tab ® platform with OPKO 's advanced protein chemistry capabilities
I believe OPKO Health will end 2026 on a high note. In partnership with Merck, Regeneron, and BARDA, it is developing ModeX's product candidates aimed at treating COVID-19, influenza, solid tumors, and blood cancers, as well as vaccines against EBV. Additionally, OPKO's balance sheet continues to strengthen, with total debt reaching $395.4 million at the end of Q3, down 22.8% year-over-year.
OPKO Health, Inc. (NASDAQ: OPK - Get Free Report) shares passed below its fifty day moving average during trading on Thursday. The stock has a fifty day moving average of $1.32 and traded as low as $1.2715. OPKO Health shares last traded at $1.28, with a volume of 1,691,533 shares. Analyst Upgrades and Downgrades Several
Positron (OTCMKTS:POSC - Get Free Report) and OPKO Health (NASDAQ: OPK - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability. Insider and Institutional Ownership 64.6% of OPKO Health
OPKO Health, Inc. (OPK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
MIAMI, Jan. 06, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (Nasdaq: OPK ) announced today that management will be participating in the 44th Annual J.P. Morgan Healthcare Conference, being held January 12-15, 2026, at the Westin St. Francis Hotel in San Francisco. Management will be hosting one-on-one meetings with investors and will be participating in a fireside chat on Wednesday, January 14th at 1:30 p.m. Pacific time.